Last reviewed · How we verify
irradiated RBC — Competitive Intelligence Brief
phase 3
Cellular immunotherapy / Cancer vaccine
Oncology / Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
irradiated RBC (irradiated RBC) — Federal Research Institute of Pediatric Hematology, Oncology and Immunology. Irradiated red blood cells act as an immunogenic cellular vaccine to stimulate anti-tumor immune responses.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| irradiated RBC TARGET | irradiated RBC | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | phase 3 | Cellular immunotherapy / Cancer vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Cellular immunotherapy / Cancer vaccine class)
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- irradiated RBC CI watch — RSS
- irradiated RBC CI watch — Atom
- irradiated RBC CI watch — JSON
- irradiated RBC alone — RSS
- Whole Cellular immunotherapy / Cancer vaccine class — RSS
Cite this brief
Drug Landscape (2026). irradiated RBC — Competitive Intelligence Brief. https://druglandscape.com/ci/irradiated-rbc. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab